New drug trial aims to slow scarring of the lungs
NCT ID NCT07503587
Summary
This study is testing whether an experimental tablet called HSK44459 can slow the progression of lung scarring in adults with progressive pulmonary fibrosis. It will compare the drug to a placebo in 378 participants over 52 weeks, measuring changes in lung function. The goal is to see if the new treatment can better control the disease than current standard care or placebo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.